Urinary low molecular weight products in neoplasia.

Wachter, H; Grassmayr, K; Gütter, W.; Hausen, Arno; Sallaberger, G.; Gabl, F

doi:10.1136/bmj.2.5757.322-a

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NP was first isolated from human urine in the 1960s. In 1979, Wachter et al 14 identified NP as one of the molecules responsible for the fluorescence of urine in cancer patients. NP is excreted from the organism in an unchanged form mainly through the kidneys 10.…”

Section: Pteridines – Structure and Metabolismmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases

et al. 2011

View full text Add to dashboard Cite

Cancer disease is the second leading cause of death in the world. Epidemiology data indicate that early diagnosis of a tumour increases a patient's chance of recovery. Biomarkers are effective instruments which can potentially lead to precancer screening or precancer diagnosis and may provide useful information on the cancer type and the disease's stage of progression. The analysis of new biomarkers for cancer is currently a popular area of study in clinical and cancer research. Pteridines are a class of potential cancer biomarkers. The monitoring levels of pteridines may have prospective value for controlling the course of the malignant process. This review describes the functional employment of pteridines, as biomarkers, in cancer diagnosis. It also contains the description of application of analytical techniques such as high-performance liquid chromatography (HPLC) and capillary electrophoresis (CE) used for pteridine analysis.

show abstract

Section: Pteridines – Structure and Metabolismmentioning

confidence: 99%

“…In women who had epithelial ovarian cancer, cervical carcinoma, endometrial carcinoma, and uterine sarcomas, NP concentrations were elevated. In patients with benign neoplasm or precancerous disorders, NP values were without any changes 14, 22.…”

Section: Pteridines In Cancer Diseasementioning

confidence: 99%

Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Alles bleibt Undefiniert und undurchsichtig, "Zauber" (Glowatzki), und gerade der Zauber stellt einen wesentlichen Anteil dieser Therapie dar -sofern der Patient darauf anspricht (Glowatzki). Daß er darauf anspricht und ihn sogar sucht, kann aus dem wirtschaftlichen Erfolg alternativer Gesundheits-Gurus und der dazugehörenden Industrie zwanglos abgeleitet werden (1,3 …”

Section: Medizin Am Rande Der Magie?unclassified

Neopterin, ein Marker der zellulären Immunantwort

Lang¹

1986

LaboratoriumsMedizin

View full text Add to dashboard Cite

Beside biochemical fundamentals the determination of Neopterin in urine and serum is described and the specific sample pretreatment stressed. Examples for the use of Neopterin in cell mediated immune response are given. In particular Neopterin is a helpful parameter in the therapy control of malignant diseases. The results of the Neopterin determination in urine in patients with malignancies can be summarized: 1. The determination of Neopterin allows an early diagnosis only in leukemiasand non Hodgkin lymphomas. 2. The Neopterin values correlate with the tumor cell mass. 3. Neopterin is valuable for therapy control. 4. Neopterin allows recognition of recidive. 5. Neopterin fs valuable in prognosis.

show abstract

“…Studies in advanced neoplasias of different sites Early reports on patients with malignancy showed a raised excretion of fluorescent urinary components, which were very probably pteridines (77,78). A pterin excreted by patients with cancer and by malignant cells in tissue culture media was originally tentatively identified äs pterin-6-aldehyde (33), but was later identified äs 6-hydroxymethylpterin (59).…”

Section: Excretion Of Pteridines In Patients With Malignant Diseasesmentioning

confidence: 99%

Pteridines in the Assessment of Neoplasia

Hausen¹,

Wachter²

1982

CCLM

View full text Add to dashboard Cite

Summary: Biological processes which inight explain the association of pteridine excretion with proliferation are still unknown. Difficulties in the analysis and the determination of naturally occurring pteridines are described. The best quantitative estimations were achieved when measurement of non-reduced forms was attempted. The performance characteristics of such a method for neppterin by high performance liquid chromatography on reversed phase are given. Enhanced proliferation and dedifferentiation in cell cultures and organisms is paralleled by excretion of unconjugated pteridines into the medium or urine. Urinary neopterin in healthy subjects and in patients with benign diseases was only significantly raised in patients with viral diseases. Howevei, an elevation of urmary neopterin occurred in a wide variety of malignant diseases. In haematologic neoplasias correlatipns of neopterin values to clinicäl features, to tumour staging, and to laboratory data were apparent. The clinicäl Utility of neopterin measurement was also demonstrated in patients with gynaecologic tumours, particularly in patients with ovarian carcinoma. In both homogenepus patient groups the neopterin assay may provide an additional aid for prognosis and for monitoring therapy. Comparison of the neopterin assay with already established tumour marker substances at least revealed no inferiority in sensitivity. The present results justify extensive investigations in prder to eväluate further the clinicäl applicäbility of the neopterin assay. Pteridine in der Diagnostik von Neoplasien

show abstract

Urinary low molecular weight products in neoplasia.

Cited by 12 publications

References 0 publications

Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases

Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases

Neopterin, ein Marker der zellulären Immunantwort

Pteridines in the Assessment of Neoplasia

Contact Info

Product

Resources

About